Literature DB >> 785990

Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion.

W J Rogers, A W Stanley, J B Breinig, J W Prather, H G McDaniel, R E Moraski, J A Mantle, R O Russell, C E Rackley.   

Abstract

Free fatty acids (FFA), the predominant myocardial energy substrate, are present in increased quantities immediately following acute myocardial infarction (AMI) and may cause deleterious alterations in cardiac rhythm, oxygen consumption, and mechanical performance. In an attempt to suppress FFA and simultaneously increase the availability of carbohydrate as a myocardial substrate, 70 patients with unequivocal AMI were administered a right atrial infusion of glucose-insulin-potassium (GIK) (300 gm. of glucose, 50 U. of regular insulin, and 80 mEq. of KC1 per liter of H2O) at a constant rate of 0.5 to 2.0 ml. per kilogram per hour for 48 hours. A dramatic fall in FFA (944 +/- 57 to 289 +/- 16 muEq per liter, p less than 0.0005) occurred during GIK infusion, and FFA rebounded to 420 +/- 39 muEq per liter (p less than 0.005) when GIK was discontinued. The hospital mortality rate in the 70 GIK recipients was compared to that of 64 untreated patients (controls) from the same coronary-care unit during the previous year. GIK and control groups had similar severity of infarction as assessed by prognostic scales of Killip, Peel, and Norris, respectively. The hospital mortality rate was reduced in the GIK recipients compared to the control group (11/70 vs. 19/64, p less than 0.05). In patients without history of prior myocardial infarction, the mortality rate was reduced four-fold in GIK recipients compared to controls (6 vs. 24 per cent, p less than 0.05). Complications of GIK infusion were infrequent and included chiefly hyperglycemia and hyperkalemia, both of which dictated meticulous monitoring of serum chemistries. The data suggest that suppression of plasma FFA with GIK infusion may be associated with a significant reduction in the hospital mortality rate of acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 785990     DOI: 10.1016/s0002-8703(76)80043-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  16 in total

1.  Glucose-insulin-potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs.

Authors:  P Zhu; L Lu; Y Xu; C Greyson; G G Schwartz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-02       Impact factor: 4.733

2.  The effect of insulin on the heart : Part 1: Effects on metabolism and function.

Authors:  L J Klein; F C Visser
Journal:  Neth Heart J       Date:  2010-04       Impact factor: 2.380

3.  The effect of insulin on the heart: Part 2: Effects on function during and post myocardial ischaemia.

Authors:  L J Klein; F C Visser
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

4.  Hypoxia and glucose independently regulate the beta-adrenergic receptor-adenylate cyclase system in cardiac myocytes.

Authors:  K J Rocha-Singh; N Y Honbo; J S Karliner
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Enhanced utilization of exogenous glucose improves cardiac function in hypoxic rabbit ventricle without increasing total glycolytic flux.

Authors:  E M Runnman; S T Lamp; J N Weiss
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

6.  Protection of ischemic myocardium.

Authors:  P W Armstrong
Journal:  Can Med Assoc J       Date:  1977-10-08       Impact factor: 8.262

Review 7.  Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction.

Authors:  U N Das
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

8.  The measurement and control of myocardial infarct size.

Authors:  M C Apps; J Tinker
Journal:  Intensive Care Med       Date:  1978-01       Impact factor: 17.440

9.  Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes: Biological mechanisms for benefit in the IMMEDIATE Trial.

Authors:  Harry P Selker; William S Harris; Charles E Rackley; Julian B Marsh; Robin Ruthazer; Joni R Beshansky; Eric J Rashba; Inga Peter; Lionel H Opie
Journal:  Am Heart J       Date:  2016-06-02       Impact factor: 4.749

Review 10.  The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes.

Authors:  Abhinav Goyal; John L Petersen; Kenneth W Mahaffey
Journal:  Curr Cardiol Rep       Date:  2004-07       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.